若生智能
Drug Database
FI

filgrastim (long-acting)

✓ Approved

Win Medica · CSF3R · 重组蛋白

什么是 filgrastim (long-acting)？

filgrastim (long-acting) 是一种重组蛋白，由Win Medica研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司Win Medica
药物类别重组蛋白
分子靶点CSF3R
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Win Medica

作用机制

分子靶点

filgrastim (long-acting) 作用于 1 个分子靶点：

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

filgrastim (long-acting) 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersBone marrow disorder✓ Approved

相关研究文献

PubMedDrug and alcohol review2026-08-04

Long-Acting Injectable Buprenorphine in Prison: Insights From a Short-Answer Survey of People in the Criminal Justice System Commencing Long-Acting Injectable Buprenorphine During a Non-Randomised Clinical Trial.

Woods Amelia A, Foley Catherine C, Dunlop Adrian A, White Bethany B et al.

Long-acting injectable buprenorphine (LAIB) is increasingly used in the Criminal Justice System (CJS) for treating people with opioid use disorder; however, little is known about these patients' experiences. We aimed to understand the perspectives of participants commenced on LAIB in prison as a part of the Understanding NSW Long-Active Opioids in Custody-Treatment (UNLOC-T) study. Results of an open-ended survey administered by UNLOC-T researchers underwent analysis. Participants were adults, recruited November 2018-July 2019, with moderate-severe opioid use disorder and ≥ 6 months remaining on their sentence. We conducted a thematic analysis using a pragmatic, descriptive coding approach. Sixty-seven participants were included, of which 82% were male. Five primary themes were identified that described participants' experiences and highlighted issues that can directly inform service delivery: medication effectiveness, social and relational considerations, dosing frequency, financial aspects, and health and wellbeing. There was considerable variation in participant perspectives within themes. Perspectives on LAIB are diverse, suggesting a need to individualise treatment and ensure person-centered care. While LAIB offers benefits to warrant including it as a treatment option, challenges remain. Future research into LAIB in the CJS would allow for triangulation, as well as further exploration of ongoing acceptability in the post-release period. Our findings could help to improve the way LAIB is offered as a treatment option or delivered to people in the CJS. There are also lessons for prescribers in counselling and tailoring treatment, and broader policy considerations around access to treatment formulations and patient autonomy.

PMID 42548035
阅读全文 →
PubMedDermatologie (Heidelberg, Germany)2026-08-04

[Current and future therapies for bradykinin-mediated angioedema].

Fasshauer Maria M, Dominas Nina N

Bradykinin-mediated angioedema, particularly hereditary angioedema due to C1 esterase inhibitor deficiency or dysfunction (HAE-C1INH), is caused by dysregulation of the kallikrein-kinin system with excessive bradykinin generation and subsequent increased vascular permeability. Modern HAE management is based on three major therapeutic strategies: on-demand treatment, short-term prophylaxis (STP), and long-term prophylaxis (LTP). On-demand treatment options include plasma-derived and recombinant C1 inhibitor (C1INH) concentrates, the bradykinin B2 receptor antagonist icatibant, and, more recently, the first orally available plasma kallikrein inhibitor, sebetralstat. Short-term prophylaxis prior to invasive medical procedures is performed as replacement therapy by intravenous administration of C1INH concentrates. The goal of long-term prophylaxis is complete disease control with reduction of attack frequency and/or severity and improvement of quality of life. LTP therapies include subcutaneous and intravenous C1INH preparations, the oral kallikrein inhibitor berotralstat, the anti-kallikrein monoclonal antibody lanadelumab, the factor XIIa inhibitor garadacimab, and the antisense oligonucleotide donidalorsen. Currently under development are the oral bradykinin B2 receptor antagonist deucrictibant, which is intended for both on-demand treatment and long-term prophylaxis in different formulations, long-acting antibodies, such as navenibart, and CRISPR/Cas9-based gene-editing therapies, such as NTLA-2002 with potential functional curative properties. In particular, orally available and long-acting therapies are expected to improve adherence, self-management, and quality of life in affected patients.

PMID 42550203
阅读全文 →
PubMedCHEST pulmonary2026-08-04

A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmission (PILLAR): A Randomized Controlled Trial.

Parrott Tate D TD, Wallace Matthew D MD, Eble Sarah H SH, Niehoff Kristina M KM et al.

COPD is a leading diagnosis for hospital readmissions and a focus of the Centers for Medicare & Medicaid Services Hospital Readmission Reduction Program, which penalizes hospitals for avoidable readmissions. Does a pharmacist-led evaluation and recommendation of chronic inhaler therapy before hospital discharge impact time to hospital readmission and emergency department (ED) visit? A single-center randomized controlled trial at a large academic medical center enrolled admitted patients prescribed a long-acting inhaler. Patients received usual care or the intervention wherein a pharmacist reviewed inhaler therapy and provided recommendations for those with inappropriate therapy based on insurance formulary preference or clinical guidelines before discharge. The primary outcome was the combined time (days) to either hospital readmission or ED visit after hospitalization measured 6 months postdischarge. Similar analyses were performed for patients with and without COPD. The study included 914 patients on long-acting inhaler therapy (56% with COPD and 33% with asthma). Fifty percent of patients were identified to have inappropriate inhaler therapy. The mean time to readmission/ED visit ± SD was 121 ± 71 days for the intervention arm and 117 ± 73 days for the usual care arm (hazard ratio [HR], 0.97; 95% CI, 0.79-1.18). Patients with COPD in the intervention arm had a lower risk of readmission/ED visit at both 30 days (HR, 0.63; 95% CI, 0.42-0.93) and 6 months (HR, 0.42; 95% CI, 0.28-0.64) compared with usual care; however, no difference was seen for patients without COPD at 30 days (HR, 1.18; 95% CI, 0.75-1.86; P = .468) and 6 months (HR, 1.5; 95% CI, 1.11-2.04; P = .009). In a group of patients receiving long-acting inhaler therapy for various indications, a significant reduction in risk of time to readmission/ED visit was not seen between the intervention and usual care groups. However, a significant reduction in risk of time to readmission/ED visit was observed for patients with COPD in the intervention group, suggesting an opportunity for pharmacist inhaler therapy review for financial and clinical appropriateness to reduce avoidable readmissions. ClinicalTrials.gov; No.NCT03927820; URL: www.clinicaltrials.gov.

PMID 42548423
阅读全文 →
PubMedCHEST pulmonary2026-08-04

An Asymptomatic 42-Year-Old Woman With Randomly Distributed Semicalcified Pulmonary Nodules.

Dimeas Ilias E IE, Tzilas Vasilios V, Tourlakopoulos Konstantinos K, Foukas Periklis G PG et al.

A 42-year-old woman with a 25 pack-year smoking history, who quit 5 years prior to presentation, was referred to our outpatient clinic for reevaluation of multiple bilateral pulmonary nodules first identified 4 years earlier on chest computed tomography, performed following a self-limited flu-like illness with transient rash and nonproductive cough. Her symptoms resolved without intervention, and she remained clinically stable in the years that followed, with only occasional episodes of dry cough; however, the radiologic findings and her medical history prompted progressive diagnostic workup. Her medical history included non-Hodgkin lymphoma treated with chemotherapy 9 years before referral, with a documented relapse 5 years earlier and no evidence of active disease in the preceding 4 years. She had undergone total thyroidectomy for benign thyroid nodules 8 years before referral and partial nephrectomy for clear cell renal carcinoma 3 years earlier. At the time of referral, she was receiving thyroid hormone replacement therapy and a long-acting beta-agonist/long-acting muscarinic antagonist inhaler prescribed by her general practitioner for intermittent cough. She had no known TB exposure, no significant travel history, and no environmental or domestic risk factors, but reported occupational exposure from prior work in a charcoal grill restaurant. She had no history of aspiration episodes and reported no symptoms suggestive of chronic aspiration or dysphagia. Persistent abnormalities on serial imaging prompted extensive investigation over the years, including 2 surgical biopsies and multiple diagnostic studies, none of which yielded a definitive diagnosis. Despite the persistent radiographic findings, including nodules of varying size and semicalcified appearance, her clinical status remained stable, and no treatment had been initiated. She was ultimately referred to the department of respiratory medicine and admitted for further evaluation.

PMID 42548508
阅读全文 →
PubMedExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2026-08-04

Kidney Transplantation from Hepatitis C-Positive Donors in the Direct-Acting Antiviral Era.

Rawashdeh Badi B, Al-Abdallat Haneen H, Mohammad Noor Haj NH, Asassfeh Ayham A et al.

The introduction of direct -acting antivirals has transformed kidney transplantation with hepatitis C virus -positive donors from a high -risk practice to a safe strategy for expanding the donor pool. This study aimed to highlight global research trends, collaborations, and shifts in hepatitis C virus -positive donor kidney transplant before and after the direct -acting antiviral era. We conducted a thorough search of the Web of Science database, focusing on research output with relevant key words related to the hepatitis C virus and kidney transplant, resulting in 414 pertinent research items. We analyzed these items using bibliometric parameters. Over the past 2 decades, notable shifts have occurred in the research trajectory, with a peak in publications observed in 2018 and 2019 following the introduction of direct -acting antivirals, followed by a decline in subsequent years. The United States generated the highest research output, followed by France and Spain. The journals Transplantation and American Journal of Transplantation dominated in terms of citations. The University of Toulouse, the University of Pennsylvania, and the University of Miami were the leading institutional contributors. The introduction of direct -acting anti -virals coincided with a rapid rise in research activity and global collaboration, reflecting the transition of hepatitis C virus -positive donor kidney transplant from a high -risk practice to routine clinical adoption.

PMID 42549788
阅读全文 →
PubMedFrontiers in sports and active living2026-08-04

Prevalence of self-reported asthma among female ice hockey players in the Swedish women's hockey league.

Lahti Amanda A, Lindman Ida I, Stenman Emelie E, Grundberg Anton A et al.

Asthma is common among athletes, particularly in winter sports, and can affect both health and performance. Ice hockey players are exposed to cold, dry air and high-intensity exertion, all recognized as triggers for asthma symptoms. However, the prevalence of asthma among female ice hockey players remains largely unknown. In this cross-sectional study, all 224 players in the 2023-2024 season of the Swedish Women's Hockey League (SDHL) were invited to an online questionnaire that included self-reported asthma, allergy, and medication use. A total of 154 players (69%) (mean age 23.3, standard deviation 4.4 years) participated. Of these, 26 (17%) had self-reported asthma, and 43 (28%) had a first-degree relative with asthma. Among players with self-reported asthma, 7 (27%) used regular medication, including corticosteroids and short-acting (SABA) and long-acting beta-agonists (LABA). Allergies were self-reported by 44 players (29%). SDHL players had 1.7 times higher odds of self-reported asthma than age-matched females in the Swedish general population (p = 0.008). Female elite ice hockey players reported a higher prevalence of asthma compared with age-matched females in the Swedish general population. These findings highlight the importance of increased awareness, appropriate screening, and continued monitoring of respiratory health in female ice hockey players, while also providing a basis for future longitudinal research as women's ice hockey continues to grow and remains underrepresented in sports medicine research.

PMID 42548751
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多filgrastim (long-acting)